Drug-assisted expectant care versus surgery for retained products of conception
Official title: A Prospective Multicenter Observational Real-world Study of Retained Products of Conception
Run by The Third Xiangya Hospital of Central South University · NCT07421895 · Data updated 2026-11-12
This project tests whether trying drug-assisted expectant management and waiting for the right time for surgery in people with retained products of conception reduces intrauterine scarring and better preserves fertility compared with immediate curettage.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 45 Years |
| Sex | Women only |
| Enrollment | 600 (estimated) |
| Sponsor | The Third Xiangya Hospital of Central South University Academic / other |
| Locations | 1 site (Changsha, Hunan) |
| Status | Recruiting |
| Started | June 1, 2022 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2032 |
| Registry record updated | February 19, 2026 |
| Trial ID | NCT07421895 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people with clinically diagnosed retained products of conception, an ultrasound lesion at least 0.5 cm in diameter, and no active bleeding, obvious infection, or severe organ dysfunction.
✕Probably not a fit
Patients with active heavy bleeding, clear infection, or severe organ dysfunction are unlikely to benefit from expectant management and will require immediate or alternative care.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective multicenter observational real-world study conducted at hospitals in Hunan, China. Patients with a clinical diagnosis of retained products of conception and an ultrasound lesion ≥0.5 cm will be followed after receiving either uterine curettage or drug-assisted expectant management until the clinician decides on surgery timing. The study will record rates of intrauterine adhesions and other fertility-related outcomes, as well as need for repeat procedures, infection, and bleeding. Patients with active bleeding requiring immediate surgery, obvious infection, or severe organ dysfunction are excluded and data will be used to compare real-world safety and effectiveness of the two approaches.
Why it matters
Potential benefit: If successful, this approach could reduce intrauterine adhesions and help preserve future fertility by avoiding or better timing surgery.
How similar studies have gone: Some prior case series and observational reports suggest expectant or medical management can reduce immediate surgical interventions, but evidence that such approaches lower intrauterine adhesion rates is limited and mixed.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:Clinical diagnosis of retained products of conception, and ultrasound indicated that the maximum diameter of the lesion ≥0.5cm. Exclusion Criteria:1) There is active bleeding requiring immediate surgical intervention;2) combined with obvious infection;3) Combined with severe organ dysfunction, including coagulation dysfunction.
Where it's running
-
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China Recruiting
Study contacts
- Study coordinator: Dabao MD
- Email: forxudabao@126.com
- Phone: 13017386201
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Operative hysteroscopy in the operating room versus the outpatient clinic
This will test whether operative hysteroscopy done in an outpatient clinic works as well as when it's done in the operating room for women treated for fibroids, polyps, or retained products of conception.
-
Intracervical vasopressin to help hysteroscopic removal of retained pregnancy tissue.
This test checks whether injecting vasopressin into the cervix during hysteroscopic removal helps women 18–51 have complete removal of retained pregnancy tissue.
-
Evaluating conservative management for retained products of conception and enhanced myometrial vascularity
This study is testing if gentle treatments for people with leftover pregnancy tissue after a miscarriage can help them recover naturally over two menstrual cycles.
-
Using hyaluronic acid gel to prevent adhesions after surgery for retained pregnancy tissue
This study is testing if a special gel can help prevent complications like infertility after surgery for leftover pregnancy tissue.
-
Hysteroscopy for treating retained products of conception after miscarriage
This study tests whether a procedure called hysteroscopy helps women who had a miscarriage and still have some pregnancy tissue to get pregnant again faster compared to just waiting it out.
-
Misoprostol versus watchful waiting for retained tissue after first-trimester medical abortion
This project will test whether taking misoprostol or simply watching and waiting works better to clear retained tissue after a first‑trimester medical abortion in women aged 18–45 with ultrasound evidence of retained products.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.